Sign in to continue:

Sunday, March 29th, 2026

GCT Semiconductor Holding, Inc. 2025 Annual Report: Financials, Risk Factors, and Corporate Governance Overview





GCT Semiconductor Inc. 10-K Key Highlights for Investors

GCT Semiconductor Inc. 2025 10-K Filing: Comprehensive Investor Update

Key Points & Shareholder Concerns

  • Annual Report Filed: GCT Semiconductor Inc. has submitted its Form 10-K for the fiscal year ended December 31, 2025, confirming compliance with all SEC reporting requirements.
  • Exchange Listing: The company’s Common Stock (GCTS) and Warrants (GCTSW) are registered and traded on the New York Stock Exchange.
  • Shares Outstanding: As of March 19, 2026, there are 72,494,116 shares of Common Stock outstanding.
  • Market Capitalization: The aggregate market value of shares held by non-affiliates is approximately \$68.2 million as of June 30, 2025, based on NYSE closing prices.
  • Company Status: GCT Semiconductor is classified as a smaller reporting company and an emerging growth company, but it is not a well-known seasoned issuer nor a shell company.
  • No ICFR Auditor Attestation: The company’s internal control over financial reporting has not been attested to by its independent auditor under Section 404(b) of Sarbanes-Oxley Act—a potential concern for risk-sensitive investors.
  • No Error Corrections: Financial statements included in the filing do not reflect corrections of errors or restatements requiring executive compensation recovery analysis.
  • Compliance: All required Interactive Data Files (XBRL) have been filed timely.
  • Key Sections for Investors:

Potential Price-Sensitive Information

  • Market Cap and Shares Outstanding: With a relatively modest market cap and substantial share count, the company may be sensitive to trading volume and news flow. Any future corporate actions (buybacks, issuance, mergers) may significantly impact share value.
  • ICFR Auditor Attestation Absent: The lack of auditor attestation on internal controls could raise governance concerns among institutional investors and potentially impact valuation.
  • Emerging Growth Company Status: The company is not using the extended transition period for new accounting standards, reducing uncertainty around future financial reporting changes.
  • SEC Compliance: Full compliance with SEC and exchange requirements reduces regulatory risk, supporting shareholder confidence.
  • Affiliates Excluded from Market Cap Calculation: Exclusion of shares held by insiders and 10%+ holders affects market cap figures and could influence perceptions of liquidity and control.

Investor Action Items

  • Review the Risk Factors section for any newly disclosed risks or evolving material threats.
  • Examine Management’s Discussion & Analysis for outlook, operational highlights, and strategic direction.
  • Monitor upcoming filings or press releases for any changes in auditor attestation status or material restatements.
  • Consider the impact of the company’s classification as a smaller reporting and emerging growth company on future regulatory obligations and potential for accelerated growth or volatility.

Conclusion

GCT Semiconductor Inc.’s 10-K filing for 2025 provides a comprehensive snapshot of its business status, regulatory compliance, and financial position. While no material restatements or corrections have occurred, the absence of auditor attestation for internal controls may be a point of concern for some investors. The company’s market cap, share trading status, and regulatory classification are all relevant for assessing investment risk and opportunity.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. Investors should review the full 10-K filing and consult with their financial advisor before making any investment decisions. The information presented is based on the latest available SEC filings and may be subject to change.




View GCT Semiconductor Holding, Inc. Historical chart here



Abeona Therapeutics Adopts Third Amended and Restated Bylaws Effective March 16, 2026

Abeona Therapeutics Inc. Adopts Third Amended & Restated Byl...

   Ad